Cyclacel Pharmaceuticals, Inc. (CYCC)
- Previous Close
0.2853 - Open
0.2335 - Bid 0.0251 x 20000
- Ask 0.4200 x 100
- Day's Range
0.2280 - 0.4100 - 52 Week Range
0.1700 - 4.0000 - Volume
105,166,697 - Avg. Volume
522,536 - Market Cap (intraday)
63.673M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0900 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
www.cyclacel.comRecent News: CYCC
View More
Performance Overview: CYCC
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCC
View MoreValuation Measures
Market Cap
59.15M
Enterprise Value
56.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.53
Price/Book (mrq)
--
Enterprise Value/Revenue
1.30k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-116.33%
Return on Equity (ttm)
--
Revenue (ttm)
43k
Net Income Avi to Common (ttm)
-11.21M
Diluted EPS (ttm)
-2.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.14M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.27M